AstraZeneca’s CAPItello-292 Study: A New Frontier in Breast Cancer Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca’s latest clinical study, titled ‘Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292),’ aims to evaluate the efficacy and safety of combining capivasertib with CDK4/6 inhibitors and fulvestrant. This study targets hormone receptor-positive and HER2-negative breast cancer that is locally advanced or metastatic, focusing on patients who have not received prior endocrine therapy in the advanced setting.

The study tests various drug combinations, including capivasertib with fulvestrant and different CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib. These combinations aim to enhance treatment efficacy for this specific breast cancer type.

The study is designed as an open-label, randomized, parallel-group trial, with no masking involved. It consists of two phases: Phase Ib for dose finding and Phase III for efficacy and safety evaluation. The primary aim is treatment-focused.

The study commenced on May 10, 2021, with an anticipated completion date in 2025. The latest update was submitted on August 12, 2025, indicating ongoing recruitment and progress.

This study could significantly impact AstraZeneca’s market position by potentially expanding its oncology portfolio. Positive outcomes might boost investor confidence and influence stock performance, especially in the competitive oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.